Segment Wise Revenue, Results & Capital Employed (Under Clause 41 of the Listing Agreement)

Particulars

Seament revenue a. Pharmaceuticals & Life

Science Products

c. Performance Polymers

Less: Inter segment revenue

Less: Excise Duty on Sales

a Pharmaceuticals & Life

Science Products

c. Performance Polymers

a. Pharmaceuticals & Life

Science Products

c. Performance Polymers

Interest

Capital Employed (Segment assets

Total Capital employed in segments

Add: Un-allocable corporate assets

Other un-allocable expenditure

(net of un-allocable income)

b. Industrial Products

Total profit before tax

less Segment liabilities) a. Pharmaceuticals & Life

Science Products

c. Performance Polymers

less liabilities

h Industrial Products

Segment results (profit(+) / loss(-) before tax and interest from each segment)

b. Industrial Products

b. Industrial Products

Gross sales

Net sales



Net Sales up EBIDTA up 59%

(Audited

Total

Less: i.

(318)

PATup

JUBILANT ORGANOSYS LTD.

Ended March 31

(Unaudited)

2007 2006

(158)

Jubilant Organosys Ltd.

Regd.Off: Bhartiagram, Gajraula, Distt. Jyotiba Phoolay Nagar - 244 223 (U.P.)

Audited Financial Results for the Year ended 31st March, 2007

CONSOLIDATED RESULTS

Quarter Ended

(Unaudited

2007 2006

(57)

(Rs. in Million)

March 31

(Audited)

(98)

2007 2006

CONSOLIDATED RESULTS				rs		JUBILANT ORGANOSYS LTD.					
9 Months Ended Dec. 31 Unaudited)	Quarter Ended March 31 (Unaudited)		Year Ended March 31 (Audited)		Particulars	9 Months Ended Dec. 31 (Unaudited)	Quarter Ended March 31 (Unaudited)		Year Ended March 31 (Audited)		
		2006		2006	2007	2006	2007	2006			
8274		2527	11116	10292	Domestic sales & services	8270	2841	2527	11111	10292	
6183	2135	1997	8318	5887	International sales	4524	1799	1464	6323	4757	
14457	4977	4524	19434	16179	Gross sales	12794	4640	3991	17434	15049	
(993)	(344)	(298)	(1337)	(1189)	Less: Excise duty on Sales	(993)	(344)	(298)	(1337)	(1189)	
13464	4633	4226	18097	14990	Net sales	11801	4296	3693	16097	13860	
403	173	96	576	197	Other income	246	64	88	310	177	
13867	4806	4322	18673	15187	Total income	12047	4360	3781	16407	14037	
11066	3836	3533	14902	12820	Total expenditure	9355	3389	3011	12744	11657	
					a) (Increase) / Decrease in stock of						
(252)	3	(52)	(249)	(186)	manufactured goods	(269)	76	(87)	(193)	(111)	
306	86	59	392	463	b) Cost of trading goods sold	263	103	32	366	403	
6050	2110	1881	8160	7142	c) Raw & process materials consumed	5818	2098	1837	7916	7013	
					d) Stores, spares, chemicals, catalyst						
795	338	222	1133	760	& packing material consumed	694	267	199	961	706	
					e) Manufacturing expenses						
962	343	265	1305	1162	Cost of power & fuel	962	336	265	1298	1162	
381	152	114	533	435	 Other manufacturing expenses 	367	145	108	512	418	
1597	552	481	2149	1360	f) Staff cost	704	271	214	975	771	
1227	252	563	1479	1684	g) Selling, general & admin. expenses	816	93	443	909	1295	
					Operating profit before interest						
2801	970	789	3771	2367	and depreciation	2692	971	770	3663	2380	
141	54	30	195	173	Interest (Net)	105	46	19	151	147	
2660	916	759	3576	2194	Operating profit before depreciation	2587	925	751	3512	2233	
457	166	155	623	513	Depreciation	384	132	128	516	442	
2203	750	604	2953	1681	Profit before tax	2203	793	623	2996	1791	
590	122	136	712	392	Provision for tax (Including Deferred Tax & Fringe Benefit Tax and net of reversals)	584	97	149	681	403	
1613	628	468	2241	1289	Net profit after tax	1619	696	474	2315	1388	
(29)	(10)	(14)	(39)	(8)	Minority Interest	_	_	-	_	-	
1642	638	482	2280	1297	Net profit after Minority Interest	1619	696	474	2315	1388	
143.4	143.5	142.5	143.5	142.5	Paid-up share capital (Face value of the share is Rs.1/-)	143.4	143.5	142.5	143.5	142.5	
			8918	8115	Reserves (excluding revaluation reserve) Earnings per share (Not annualized)				9473	8102	
11.48	4.44	3.52	15.93	9.48	Basic (Rs.)	11.32	4.85	3.47	16.17	10.15	
9.44	3.59	3.17	13.02	8.57	Diluted (Rs.)	9.31	3.91	3.12	13.22	9.17	
					Aggregate of non-promoter shareholding						
69064310	69067310	68452650	69067310	68452650	Number of shares (Re. 1 each)	69064310	69067310	68452650	69067310	68452650	
48.15	48.15	48.06	48.15	48.06	 Percentage of shareholding 	48.15	48.15	48.06	48.15	48.06	

SYS L	TD.	
En Marc	ear ded ch 31 lited)	
007	2006	9 Month
11111	10292	Ended Dec. 31
6323	4757	(Unaudite
17434	15049	2006
1337)	(1189)	
16097	13860	7104
310	177	570
16407	14037	1708
12744	11657	
		1451
(193)	(111)	60
366	403	993
7916	7013	1346
961	706	6880
		507
1298	1162	150
512	418	1346
975	771	
909	1295	
3663	2380	1324
151	147	663
3512	2233	96
516	442	208
2996	1791	14
681	403	(004
2315	1388	(261
_	_	220
2315	1388	
143.5	142.5	
		13574
9473	8102	387
		470
16.17	10.15	
13.22	9.17	1792
067310	68452650	8420
48.15	48.06	2634 ⁻
70.10	15.00	2034

- 1. The Board of Directors in the meeting held on 24th April, 2007, has approved acquisition of 100% stake in Hollister-Stier Laboratories LLC., a US-based company engaged in contract manufacture of sterile injectables vials and producer of allergenic extracts. The acquisition is on a debt-free, cash-free basis for a purchase consideration of US\$ 122.50 million in cash for the existing business and also the company will reimburse capital expenditure of US\$ 16 million through 31st March, 2007 and certain cash capital expenditure until the date of closing for planned capacity expansion. The transaction is subject to customary closing conditions and necessary requisite regulatory approvals.
- 2. During the Quarter, the Board of Directors have approved, the Company's entry into Health Care Business by approving an investment upto Rs.800 million in the Equity of an existing Company engaged in Health Care Business to acquire upto 96% stake

3.	During the Quarter, under the Jubilant Employees Stock Option Plan,2005, 45700 options have been granted at an
	exercise price of Rs.258.25 per share. 3000 shares were allotted on exercise of 600 vested options.

4.	The Board has recommended a dividend of Rs. 1	.25	per equity	share of Re.1	, totaling to Rs.209.78	million,	subject to
	approval in Annual General Meeting.						

Total capital employed in the Company

- 5. Information on investors complaints for the quarter (Nos.): Opening Balance Nil, New 49, Disposals 49, Closing Balance - Nil.
- 6. Figures for previous period / year have been regrouped / reclassified / restated, wherever considered necessary.
- 7. The above Financial Results were reviewed by the Audit Committee and were taken on record by the Board of Directors at its meeting held on 27th April, 2007.

For Jubilant Organosys Ltd.

Shyam S Bhartia Chairman & Managing Director

Place: Noida

Dated: 27th April, 2007